Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.

Jain N, Reilly RF.

Clin J Am Soc Nephrol. 2018 May 25. pii: CJN.02170218. doi: 10.2215/CJN.02170218. [Epub ahead of print]

PMID:
29802125
2.

Hungry bone syndrome.

Jain N, Reilly RF.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):250-255. doi: 10.1097/MNH.0000000000000327. Review.

PMID:
28375869
3.

We Use Too Much Vitamin D in Hemodialysis Patients.

Reilly RF.

Semin Dial. 2016 Jul;29(4):320-2. doi: 10.1111/sdi.12499. Epub 2016 Apr 13.

PMID:
27075415
4.

Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.

Jain N, Reilly RF.

Semin Dial. 2016 Sep;29(5):374-81. doi: 10.1111/sdi.12484. Epub 2016 Apr 8. Review.

PMID:
27061079
5.

Medical and surgical care during the American Civil War, 1861-1865.

Reilly RF.

Proc (Bayl Univ Med Cent). 2016 Apr;29(2):138-42.

6.

BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.

Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF; VA NEPHRON-D Study Group.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2159-69. doi: 10.2215/CJN.02850315. Epub 2015 Oct 19.

7.

Hypokalemia Associated with Colonic Pseudo-Obstruction (Ogilvie's Syndrome).

Sunnoqrot N, Reilly RF.

Case Rep Nephrol Dial. 2015 May 28;5(2):118-23. doi: 10.1159/000431086. eCollection 2015 May-Aug.

8.

Effects of dietary interventions on incidence and progression of CKD.

Jain N, Reilly RF.

Nat Rev Nephrol. 2014 Dec;10(12):712-24. doi: 10.1038/nrneph.2014.192. Epub 2014 Oct 21. Review.

PMID:
25331786
9.

Are calcium-based phosphate binders ever preferable in dialysis patients?

Jain N, Reilly RF.

Semin Dial. 2014 May-Jun;27(3):269-72. doi: 10.1111/sdi.12219. Epub 2014 Mar 13. Review. No abstract available.

PMID:
24620781
10.

Attending rounds: A patient with intradialytic hypotension.

Reilly RF.

Clin J Am Soc Nephrol. 2014 Apr;9(4):798-803. doi: 10.2215/CJN.09930913. Epub 2014 Jan 2.

11.

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators.

N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9. Erratum in: N Engl J Med. 2014;158:A7255.

PMID:
24206457
12.

Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?

Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF.

Clin J Am Soc Nephrol. 2013 Apr;8(4):665-74. doi: 10.2215/CJN.06790712. Epub 2012 Sep 27. Review.

13.

Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial.

Banerjee S, Das TS, Abu-Fadel MS, Dippel EJ, Shammas NW, Tran DL, Zankar A, Varghese C, Kelly KC, Weideman RA, Little BB, Reilly RF, Addo T, Brilakis ES.

J Am Coll Cardiol. 2012 Oct 9;60(15):1352-9. doi: 10.1016/j.jacc.2012.05.042. Epub 2012 Sep 12.

14.

Risk factors: filling in the gap.

Jain N, Reilly RF.

Nat Rev Nephrol. 2012 Oct;8(10):562-3. doi: 10.1038/nrneph.2012.188. Epub 2012 Aug 14. No abstract available.

PMID:
22890182
15.

Predictors of hyperkalemia and death in patients with cardiac and renal disease.

Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S.

Am J Cardiol. 2012 May 15;109(10):1510-3. doi: 10.1016/j.amjcard.2012.01.367. Epub 2012 Feb 18.

PMID:
22342847
16.
17.

Reasons to value the health care intangible asset valuation.

Reilly RF.

J Health Care Finance. 2012 Winter;39(2):37-51.

PMID:
23971140
18.

Cost approach of health care entity intangible asset valuation.

Reilly RF.

J Health Care Finance. 2012 Winter;39(2):1-36.

PMID:
23971139
19.

Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences.

Hedayati SS, Minhajuddin AT, Ijaz A, Moe OW, Elsayed EF, Reilly RF, Huang CL.

Clin J Am Soc Nephrol. 2012 Feb;7(2):315-22. doi: 10.2215/CJN.02060311. Epub 2011 Nov 23.

20.

The mechanism of hypocalciuria with NaCl cotransporter inhibition.

Reilly RF, Huang CL.

Nat Rev Nephrol. 2011 Sep 27;7(11):669-74. doi: 10.1038/nrneph.2011.138. Review.

PMID:
21947122
21.

Gadolinium and nephrogenic systemic fibrosis: have we overreacted?

Penfield JG, Reilly RF.

Semin Dial. 2011 Sep-Oct;24(5):480-6. doi: 10.1111/j.1525-139X.2011.00945.x. Epub 2011 Sep 13.

PMID:
21913988
22.

Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation?

Yalamanchili V, Reilly RF.

Semin Dial. 2011 Jul-Aug;24(4):387-8. doi: 10.1111/j.1525-139X.2011.00885.x. No abstract available.

PMID:
21851395
23.

Spondylodiscitis in a patient on chronic hemodialysis.

Afshar M, Reilly RF.

Nat Rev Nephrol. 2011 Aug 16;7(10):599-604. doi: 10.1038/nrneph.2011.105. Review.

PMID:
21844911
24.

Non-pharmacological aspects of blood pressure management: what are the data?

Hedayati SS, Elsayed EF, Reilly RF.

Kidney Int. 2011 May;79(10):1061-70. doi: 10.1038/ki.2011.46. Epub 2011 Mar 9. Review.

25.

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.

Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, Rao SV, Kastrati A, de Lemos JA, Brilakis ES, Bhatt DL.

Am J Cardiol. 2011 Mar 15;107(6):871-8. doi: 10.1016/j.amjcard.2010.10.073. Epub 2011 Jan 19.

PMID:
21247527
26.

Imaging patients with kidney disease: how do we approach contrast-related toxicity?

Perazella MA, Reilly RF.

Am J Med Sci. 2011 Mar;341(3):215-21. doi: 10.1097/MAJ.0b013e3181f016e6.

PMID:
21139495
27.

Unfractionated heparin for hemodialysis: still the best option.

Cronin RE, Reilly RF.

Semin Dial. 2010 Sep-Oct;23(5):510-5. doi: 10.1111/j.1525-139X.2010.00770.x. Review.

28.

Hereditary disorders of renal phosphate wasting.

Alizadeh Naderi AS, Reilly RF.

Nat Rev Nephrol. 2010 Nov;6(11):657-65. doi: 10.1038/nrneph.2010.121. Epub 2010 Oct 5. Review.

PMID:
20924400
29.

The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis.

Reilly RF, Peixoto AJ, Desir GV.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1893-903. doi: 10.2215/CJN.04670510. Epub 2010 Aug 26. Review.

30.

Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion?

Vigen R, Weideman RA, Reilly RF.

Int Urol Nephrol. 2011 Sep;43(3):813-9. doi: 10.1007/s11255-010-9824-6. Epub 2010 Aug 25.

31.

Intangible asset valuation, damages, and transfer price analyses in the health care industry.

Reilly RF.

J Health Care Finance. 2010 Spring;36(3):24-33.

PMID:
22329328
32.

Heparin-induced thrombocytopenia: a renal perspective.

Syed S, Reilly RF.

Nat Rev Nephrol. 2009 Sep;5(9):501-11. doi: 10.1038/nrneph.2009.125. Epub 2009 Jul 28. Review.

PMID:
19636331
33.

Rhabdomyolysis: a review, with emphasis on the pediatric population.

Elsayed EF, Reilly RF.

Pediatr Nephrol. 2010 Jan;25(1):7-18. doi: 10.1007/s00467-009-1223-9. Review.

PMID:
19529963
34.

Primary care approach to proteinuria.

Naderi AS, Reilly RF.

J Am Board Fam Med. 2008 Nov-Dec;21(6):569-74. doi: 10.3122/jabfm.2008.06.070080. Review.

35.

Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality.

Banerjee S, Varghese C, Samuel J, Weideman RA, Little BB, Kelly KC, Rao SV, Reilly RF, Brilakis ES.

Am J Cardiol. 2008 Nov 1;102(9):1159-62. doi: 10.1016/j.amjcard.2008.06.058. Epub 2008 Sep 11.

PMID:
18940284
36.

Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Reilly RF.

Clin J Am Soc Nephrol. 2008 May;3(3):747-51. doi: 10.2215/CJN.05721207. Epub 2008 Feb 20.

37.

Hereditary etiologies of hypomagnesemia.

Naderi AS, Reilly RF Jr.

Nat Clin Pract Nephrol. 2008 Feb;4(2):80-9. doi: 10.1038/ncpneph0680. Review.

PMID:
18227801
38.

Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.

Perazella MA, Reilly RF.

Semin Dial. 2008 Mar-Apr;21(2):171-3. doi: 10.1111/j.1525-139X.2007.00402.x. Epub 2008 Jan 23. Review.

PMID:
18226005
39.

Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?

Penfield JG, Reilly RF.

Semin Dial. 2008 Mar-Apr;21(2):129-34. doi: 10.1111/j.1525-139X.2007.00408.x. Epub 2008 Jan 23. Review.

PMID:
18225999
40.

What nephrologists need to know about gadolinium.

Penfield JG, Reilly RF Jr.

Nat Clin Pract Nephrol. 2007 Dec;3(12):654-68. Review.

PMID:
18033225
41.

Hypophosphatemia: an evidence-based approach to its clinical consequences and management.

Amanzadeh J, Reilly RF Jr.

Nat Clin Pract Nephrol. 2006 Mar;2(3):136-48. Review.

PMID:
16932412
42.

Retroperitoneal fibrosis presenting as acute renal failure.

Reilly RF Jr.

Nat Clin Pract Nephrol. 2005 Nov;1(1):55-9; quiz, 1 p following 59.

PMID:
16932364
43.

Anticoagulation and continuous renal replacement therapy.

Amanzadeh J, Reilly RF Jr.

Semin Dial. 2006 Jul-Aug;19(4):311-6. Review.

PMID:
16893409
44.

Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.

Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF.

Nephrology (Carlton). 2006 Apr;11(2):142-6.

PMID:
16669977
45.

Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection.

Brewster UC, Coca SG, Reilly RF, Perazella MA.

Nephrology (Carlton). 2005 Apr;10(2):124-8.

PMID:
15877670
46.

Vascular access surveillance: evaluation of combining dynamic venous pressure and vascular access blood flow measurements.

Hoeben H, Abu-Alfa AK, Reilly RF, Aruny JE, Bouman K, Perazella MA.

Am J Nephrol. 2003 Nov-Dec;23(6):403-8. Epub 2003 Oct 17.

PMID:
14566106
47.

Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease.

Perazella MA, Ishibe S, Perazella MA, Reilly RF.

Semin Dial. 2003 May-Jun;16(3):276-80.

PMID:
12753692
48.

The pathophysiology of immune-mediated heparin-induced thrombocytopenia.

Reilly RF.

Semin Dial. 2003 Jan-Feb;16(1):54-60. Review.

PMID:
12535302
49.

Chronic kidney disease: a new approach to an old problem.

Reilly RF, Perazella MA.

Conn Med. 2002 Oct;66(10):579-83. Review.

PMID:
12448208
50.

Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors.

Reilly RF, Tray K, Perazella MA.

Am J Kidney Dis. 2001 Oct;38(4):E23.

PMID:
11576910

Supplemental Content

Loading ...
Support Center